glp-1 medications mechanism of action of [25] GLP-1 Therapy Part 1: Setting

doi: 10.1111/dom.12932 178 FriedrichsenMBreitschaftATadayonSWizertASkovgaardD

Plasma insulin (ng/mL) was assessed using a wide-range Ultra Sensitive Mouse Insulin ELISA Kit (Crystal Chem, Cat #90080)

Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum

The two primary endpoints were the Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ-CSS, which ranges from 0 to 100) and the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS)

The average reported weight loss aligns with what clinical trials predict: 10 to 15 percent of starting body weight over approximately 6 to 12 months

A meta-analysis that combined data from systematic reviews and meta-analyses came to the conclusion that there was likely no increase in the risk of diabetic retinopathy from any of the diabetes drugs.[ref] However, this is still a side effect to be aware of and talk with your doctor about your individual risk